New Wave of ADCs Transforms Metastatic Breast Cancer Treatment Options
Antibody-drug conjugates are showing remarkable results in metastatic breast cancer, but sequencing and side-effect management remain key challenges.
Summary
Antibody-drug conjugates (ADCs) are rapidly expanding treatment options for women with metastatic breast cancer, particularly triple-negative subtypes. At the ASCO meeting, oncologist Paolo Tarantino highlighted promising trial data for several ADCs — including sacituzumab govitecan, datopotamab deruxtecan, and the newer izalontamab brengitecan from China — which improved both progression-free and overall survival. However, these drugs carry significant toxicities such as neutropenia, anemia, mouth sores, and eye irritation. Clinicians are being urged to proactively manage these side effects with practical measures like mouthwash and eye drops. A major upcoming challenge is determining the optimal sequence in which to use these agents as more become available.
Detailed Summary
Antibody-drug conjugates — a class of targeted cancer therapies that link a tumor-seeking antibody to a cell-killing drug — are transforming how women with metastatic breast cancer are treated. Multiple positive trials presented at the American Society of Clinical Oncology meeting signal a new era in oncology, but they also introduce complex new clinical decisions.
Three ADCs stood out in recent data. Sacituzumab govitecan (Trodelvy) showed continued strong performance in triple-negative breast cancer across the ASCENT-03 and ASCENT-04 trials. Datopotamab deruxtecan (Dato-DXd) added further evidence for its role across breast cancer subtypes. Perhaps most notably, izalontamab brengitecan, a newer ADC developed in China, demonstrated significant improvements in both progression-free survival and overall survival in Chinese patients with triple-negative disease.
Despite their effectiveness, ADCs are not without risk. Izalontamab brengitecan, for instance, was associated with substantial rates of neutropenia and anemia. Dato-DXd presents its own toxicity profile, including oral mucositis and ocular side effects. Tarantino emphasized that clinicians must learn to anticipate and actively manage these complications — using mouthwash, eye drops, and advising patients to avoid contact lenses.
One of the most pressing questions now facing oncologists is how to sequence these drugs. As multiple effective ADCs become available, choosing which to use first, second, or third — and in which subtypes — will require careful study. Tarantino noted this will demand both real-world evidence and prospective clinical trials before clear guidance emerges.
For health-conscious readers, this development is significant: it represents real, measurable progress in treating one of the most aggressive forms of breast cancer. While these are specialized oncology treatments rather than lifestyle interventions, the improving survival data underscore how rapidly precision medicine is advancing for women with late-stage disease.
Key Findings
- Izalontamab brengitecan improved both progression-free and overall survival in women with triple-negative metastatic breast cancer.
- Sacituzumab govitecan showed continued efficacy across ASCENT-03 and ASCENT-04 trials in metastatic triple-negative breast cancer.
- ADC toxicities including neutropenia, anemia, mouth sores, and eye irritation require proactive clinical management strategies.
- Optimal sequencing of multiple ADCs is the next major challenge, requiring real-world data and prospective trials.
- Dato-DXd side effects can be mitigated with mouthwash, eye drops, and avoiding contact lenses during treatment.
Methodology
This is a meeting coverage news report based on a video interview with a Dana-Farber Cancer Institute oncologist at the ASCO conference. Evidence is drawn from multiple clinical trials including ASCENT-03, ASCENT-04, and data on izalontamab brengitecan. The article represents expert opinion and trial summaries rather than a peer-reviewed publication.
Study Limitations
The article is brief and based on a short video transcript; no full trial data or statistics are presented. Results for izalontamab brengitecan come from Chinese patient populations and may not generalize globally. Sequencing strategies remain unresolved and should not be extrapolated from current data without further evidence.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: